Results 221 to 230 of about 180,170 (299)

Toward a cure for multiple myeloma within a decade. [PDF]

open access: yesBlood Cancer J
Mohty M   +3 more
europepmc   +1 more source

Protein Profile of Multiple Myeloma‐Derived Extracellular Vesicles for the Discovery of Novel Myeloma‐Related Biomarkers

open access: yesCancer Science, EarlyView.
Comparison of extracellular vesicles with parental cells through proteomic profiling, followed by an integrated bioinformatic pipeline including disease association and transcriptomic analyses, identifies candidate biomarkers for multiple myeloma. Among these, MIF emerges as a clinically relevant marker, supported by validation in patient samples and ...
Natalia Platonova   +13 more
wiley   +1 more source

The Role of CD56 as an Immunophenotypic Marker in the Clinical Course of Multiple Myeloma. [PDF]

open access: yesJ Clin Med
Karabekov A   +17 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

open access: yesCancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi   +2 more
wiley   +1 more source

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature

open access: yesCurrent Problems in Cancer: Case Reports
Noa Biran   +19 more
doaj   +1 more source

Karyotype evolution of multiple myeloma. [PDF]

open access: yesJ Clin Exp Hematop
Matsumoto Y   +10 more
europepmc   +1 more source

Integrated Engineering of CAR‐T Cells for Solid Tumours

open access: yesCell Proliferation, EarlyView.
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang   +5 more
wiley   +1 more source

Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. [PDF]

open access: yesAnn Med Surg (Lond)
Ali H   +4 more
europepmc   +1 more source

Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy